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Objective: Amrinone, a selective phosphodiesterase III inhibitor, is reported
to have a potent inotropic effect on the left ventricle, but the effects of this
drug on right ventricular contractility in the clinical setting are unknown.
The concept of ventricular/arterial coupling was applied to investigate the
effects of amrinone on right ventricular contractility and afterload with
transesophageal echocardiography. Methods and results: The study was
performed in the intensive care unit with 11 patients who had undergone
cardiac operations. Right ventricular cross-sectional area was measured
with transesophageal echocardiography equipped with a capability of
automated border detection as a surrogate for right ventricular volume.
Multiple pressure-area loops were obtained by reducing preload to measure
end-systolic elastance and effective arterial elastance. External work and
pressure-volume area were also measured to calculate the efficiency of
energy transfer from pressure-volume area to external work. Nitroprusside
(0.3 to 0.5 mg z kg-1 z min-1) and amrinone (1 mg z kg-1 intravenously fol-
lowed by 10 mg z kg-1 z min-1) were administered. With nitroprusside infu-
sion, end-systolic elastance and effective arterial elastance remained un-
changed (end-systolic elastance, 4.73 6 2.18 mm Hg/cm2 to 4.65 6 2.09 mm
Hg/cm2; effective arterial elastance, 8.05 6 3.84 mm Hg/cm2 to 7.70 6 3.64
mm Hg/cm2). In contrast, amrinone reduced afterload (effective arterial
elastance, 8.82 6 3.99 mm Hg/cm2 to 7.05 6 4.01 mm Hg/cm2, p 5 0.004)
and enhanced contractility (end-systolic elastance, 4.47 6 1.79 mm Hg/cm2
to 6.56 6 2.22 mm Hg/cm2, p 5 0.007). Consequently, amrinone decreased
the ventricular/arterial coupling ratio (effective arterial elastance/end-
systolic elastance, 2.40 6 1.45 to 1.16 6 0.63, p 5 0.009) and improved the
efficiency of energy transfer (external work/pressure-volume area, 0.44 6
0.15 to 0.54 6 0.15, p 5 0.013). Conclusions: Right ventricular pressure-area
relations obtained with transesophageal echocardiography could success-
fully separate the simultaneous change in right ventricular systolic me-
chanics and afterload caused by amrinone. Amrinone caused enhancement
of right ventricular contractility and afterload reduction. (J Thorac Car-
diovasc Surg 1998;116:139-47)
Among clinically applicable inotropic agents, am-rinone, a selective phosphodiesterase III inhibi-
tor, has been shown to have a positive inotropic
effect with remarkable vasodilatory effect.1, 2 Right
ventricular afterload may be acutely elevated after
termination of cardiopulmonary bypass because of
the inflammatory reaction associated with extracor-
poreal circulation that causes pulmonary hyperten-
sion and lung injury.3 In patients after cardiac
operations, amrinone reduces pulmonary artery
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pressure, presumably as the result of reducing right
ventricular afterload, but its effect of enhancement
on right ventricular contractility has not been dem-
onstrated.4 That may relate to the difficulties of
assessing the load-independent parameters of right
ventricular contractility. To use inotropic agents
safely in patients with postoperative right ventricu-
lar dysfunction, it is essential to assess the relative
contributions of positive inotropism and vasodilative
actions of the agents.
We, therefore, applied the framework of pres-
sure-volume relations and the concept of ventricu-
lar/arterial coupling to evaluate right ventricular
performance. Ventricular/arterial coupling is a con-
cept built on the framework of the ventricular
pressure-volume relation.5 This concept enables one
to discriminate between the positive inotropic and
vasodilatory effect of the agents. Accordingly, the
purpose of this study was to investigate the effects of
amrinone on right ventricular contractility and right
ventricular afterload in the patients who had under-
gone cardiac operation with a transesophageal echo-
cardiography and catheter tip micromanometer to
construct right ventricular pressure–cross-sectional
area loops.
Methods
Patients. Studies were attemped in 13 patients who un-
derwent elective cardiac operations. The study protocol was
approved by the Human Subjects Committee of our institu-
tion. Informed consent was obtained from all the patients,
who were hemodynamically stable in the intensive care unit
at the time of study. Two patients were excluded because of
poor quality echocardiographic images. The study group
therefore consisted of 11 patients: 9 men and 2 women, aged
49 6 14 years (range, 20 to 64 years). The operations
performed were closure of atrial septal defect (n 5 2),
closure of atrial septal defect and mitral valve repair (n 5 2),
mitral valve replacement and tricuspid annuloplasty (n 5 3),
mitral valve repair and tricuspid annuloplasty (n 5 2), mitral
valve replacement and maze procedure (n 5 1), and closure
of atrial septal defect, mitral valve repair, and maze proce-
dure (n 5 1). None of the patients was in right ventricular
failure or dysfunction evidenced by elevated right ventricular
end-diastolic pressure.
Instrumentation. After surgery, patients were trans-
ferred to the intensive care unit and received controlled
ventilation. The setting of the ventilator was unchanged
(inspired oxygen fraction, 0.40 to 0.70; inspiration/expira-
tion ratio, 1:2; positive end-expiratory pressure, 1 to 4 mm
Hg) throughout the protocol for each patient. We posi-
tioned a rapid-response thermistor pulmonary artery cath-
eter (7.5F Swan-Ganz catheter, model 93A-431H; Baxter
Healthcare Corp., Santa Ana, Calif.) in the pulmonary
artery and a catheter-tip micromanometer (Sentron; AC
Roden, The Netherlands) in the right ventricle. These two
catheters were inserted percutaneously in the operating
room after the induction of anesthesia. A 5 MHz om-
niplane transesophageal echocardioscope (model HP
21362C; Hewlett-Packard, Andover, Mass.) was inserted
to obtain a cross-sectional view of the right ventricle at the
midpapillary muscle level of the left ventricle. Echocar-
diographic images were acquired with a Hewlett-Packard
Sonos 2500 echocardiographic system (model M2406A;
Hewlett-Packard) with automated border detection
(ABD) capabilities. Images were recorded from the trans-
gastric right ventricular mid–short-axis plane, at the left
Fig. 1. An echocardiographic image in which the ABD outlines the blood-tissue interface, and the region
of interest is circled in the right ventricular cavity. The right ventricular cross-sectional area signal appears
at the bottom.
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ventricular midpapillary muscle level as an anatomic
landmark. A region of interest was then drawn manually
immediately beyond the right ventricular endocardial
border to exclude the left ventricular cavity and low-
density ultrasound signals that may appear within the
lateral myocardium (Fig. 1). Once the image had been
established, the same region of interest and the gain
setting were maintained throughout the protocol for each
patient.
Protocol. The start of the protocol was about 5 hours
after the removal of the aortic crossclamp. A time line of
the protocol is given in Fig. 2. At first, the thermodilution
cardiac output was measured, and the right ventricular
pressure and cross-sectional area were recorded simulta-
neously to obtain steady-state beat data. Then a nitroglyc-
erin (0.05 to 0.1 mg) bolus, intravenously, was made to
reduce right ventricular peak pressure by 15% to obtain
multiple pressure-area loops at different preload. These
measurements were performed at baseline, after nitro-
prusside infusion, at repeat baseline, and after amrinone
infusion (Fig. 2).
We administered nitroprusside as a pure dilator to
compare the effects of amrinone. After baseline measure-
ments, nitroprusside was infused intravenously at an ini-
tial rate of 0.3 mg z kg–1 z min–1, with the dose raised in
increments of 0.2 mg z kg–1 z min–1 until the mean arterial
pressure had fallen to 80% of baseline. Similar measure-
ments were made 30 minutes after the start of infusion.
After discontinuation of nitroprusside, systemic arterial
pressure, pulmonary artery pressure, and cardiac output
were permitted to return to the baseline values. The
repeat baseline hemodynamics and right ventricular pres-
sure–area recordings were made. Amrinone was then
infused intravenously at an initial bolus of 1 mg z kg–1 over
a 10-minute period, followed by 10 mg z kg–1 z min–1 drip
infusion. After a wait of at least 30 minutes for the
stabilization of pressures and cardiac output, final hemo-
dynamic and right ventricular pressure–area recordings
were made.
Other cardiotonic agents, such as dopamine (dose, 0 to
10 mg z kg–1 z min–1; mean, 2.9 mg z kg–1 z min–1) and do-
butamine (dose, 0 to 8 mg z kg–1 z min–1; mean, 3.7 mg z kg–
1 z min–1) or vasodilating drugs (isosorbide dinitrate in a
dose of 0 to 0.90 mg z kg–1 z min–1; mean, 0.32
mg z kg21 z min–1) were unchanged during the protocol for
each patient.
Data acquisition and analysis. Right ventricular, left
atrial, radial artery, pulmonary artery and central venous
pressure, carbon dioxide concentration of expiratory gas
waveform, and electrocardiographic (lead II) signals were
monitored on a bedside monitor (M1166A; Hewlett-Pack-
ard, Inc., Sunnyvale, Calif.). All these signals and the analog
right ventricular area signal from the echocardiography
machine equipped with the ABD system were on-line,
digitized at 200 Hz with an analog-to-digital converter (Mac
Lab System; AD Instruments, Ltd., Dunedin North, New
Zealand) and recorded on a laptop computer (Macintosh
Power Book 550C; Apple Computer, Inc., Cupertino, Calif.).
The right ventricular pressure and area signals were plotted
to display pressure-area loops in real time. To synchronize
right ventricular pressure data with the area data from the
echocardiographic ABD system, the electrocardiography
signals from both the patient monitors and the ABD system
were recorded simultaneously. It has been known that there
is a delay in right ventricular area signal.6 Our preliminary
study directly comparing ventricular volume and area signal
showed that the delay was 40 msec. Accordingly we ad-
vanced the right ventricular area signal by 40 msec in all
patients.
From the beats obtained at a steady state, maximal
cross-sectional area (Amax) and minimal cross-sectional
area (Amin) were obtained. Stroke area (SA; SA 5 Amax
2 Amin) and fractional area change (FAC; FAC 5
SA/Amax) were calculated. SA and FAC were used as the
echocardiographic equivalents of stroke volume and ejec-
tion fraction, respectively. End-systolic elastance (Ees)
and the area axis intercept (A0) of the end-systolic pres-
sure-area relationship (ESPAR) were obtained in the
following method: During the nitroglycerin bolus injection
(0.05 to 0.1 mg), only the data during end-expiratory
periods were selected for the analysis to minimize the
effects of positive-pressure ventilation. For each beat
during the nitroglycerin infusion, the point of maximal
pressure/area was first determined. A least-squares linear
regression was applied to generate slope (Ees) and inter-
cept (A0). With this A0 estimate, the points of maximal
(P/[A 2 A0]) for each loop were recalculated, where P and
A are right ventricular pressure and area, respectively,
and a second regression was used to determine new
estimates for Ees and A0. This process was continued until
the change between successive iterations for each param-
eter was less than 0.01. Once A0 was obtained, the end-
Fig. 2. A time line of the protocol. The conventional hemodynamics data, steady-state beat right ventricular
pressure-area data, and multiple pressure-area loops by the bolus nitroglycerin intravenously (IV) were
measured at baseline, after nitroprusside infusion, at repeat baseline, and after amrinone infusion.
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systolic point (Aes, Pes) of the steady-state beats was deter-
mined as the point that gave the maximal (P/[A 2 A0]),
where Aes and Pes are right ventricular end-systolic area and
pressure, respectively. To determine the position of the
ESPAR in the operating range, the area associated with the
Pes of 25 mm Hg was calculated as: A25 5 A0 1 25/Ees.
The effective arterial elastance (Ea) of the pulmonary
artery was calculated as Pes/SA. The coupling between the
right ventricle and the pulmonary artery was determined
by calculating Ea/Ees.
The total mechanical energy generated by ventricular
contraction, defined by the pressure-volume area (PVA),
was obtained as the area circumscribed by the end-systolic
trajectory of the pressure-area loop, the end-systolic pres-
sure-area line, and the end-diastolic pressure-area rela-
tionship. External work (EW) was calculated as the area
inside the pressure-area loop. EW is equivalent to stroke
work. The efficiency of energy transfer from PVA to EW
in the right ventricle was evaluated as EW/PVA.
Statistics. Results are presented as mean 6 standard
deviation. A repeated-measures of analysis of variance
was used to determine the null hypothesis that the vari-
ables at the four points (baseline, nitroprusside, repeat
baseline, and amrinone) were equal. If the null hypothesis
was rejected by the p value less than 0.05, Bonferroni’s
adjustment was performed to examine the difference
between the values of each intervention and its corre-
sponding baseline values. Because Ees and A0 are covari-
ant via a linear regression equation, multiple linear re-
gression analysis was performed by introducing two sets of
dummy variables, one for the protocol (before and after
drug infusion) and another for the patients.6 For all
statistical analyses, SPSS (version 6.1J for the Macintosh;
SPSS, Inc., Chicago, Ill.) was used.
Results
Effects of nitroprusside and amrinone on conven-
tional hemodynamic variables. The effects of nitro-
prusside and amrinone on hemodynamic variables
obtained from the thermodilution catheter are
shown in Table I. With amrinone administration,
the heart rate tended to be higher (from 90.6 6 5.8
beats/min to 96.3 6 9.4 beats/min), but neither drug
significantly altered the heart rate. Both nitroprus-
side and amrinone significantly reduced mean arte-
rial pressure and pulmonary artery pressure. Left
atrial pressure decreased with amrinone (from 9.0 6
2.3 mm Hg to 7.7 6 2.0 mm Hg, p 5 0.038) but not
with nitroprusside (from 8.5 6 2.3 mm Hg to 7.6 6
2.7 mm Hg, p . 0.2). Central venous pressure did
not change significantly with either of the drugs.
When nitroprusside was administered, there were
no significant changes in cardiac output, stroke
volume, and pulmonary vascular resistance, except
for systemic vascular resistance (from 1525 6 683
dyne z sec z cm–5 to 1273 6 518 dyne z sec z cm–5, p 5
0.020). Amrinone did not cause the changes in
systemic vascular resistance (from 1576 6 906
dyne z sec z cm–5 to 1043 6 379 dyne z sec z cm–5, p 5
0.060), cardiac output (from 4.80 6 2.27 L z min–1 to
5.39 6 1.92 L z min–1, p 5 0.122), stroke volume
(from 52.5 6 23.4 ml to 55.4 6 18.3 ml), and
pulmonary vascular resistance (from 249 6 177
dyne z sec z cm–5 to 185 6 122 dyne z sec z cm–5).
Right ventricular ejection fraction from the rapid
response thermodilution catheter did not show sig-
nificant change with neither drug.
Effects of nitroprusside and amrinone on ventric-
ular/arterial coupling and mechanical efficiency.
Representative right ventricular pressure-area loops
before and after nitroprusside and amrinone admin-
istration obtained by the bolus nitroglycerin intrave-
nously are shown in Fig. 3. Multiple linear regres-
Table I. Effect of nitroprusside and amrinone on hemodynamic variables
Baseline Nitroprusside Repeat baseline Amrinone
Repeated measure
of ANOVA
Heart rate (beats/min) 89.1 6 9.4 91.1 6 10.1 90.6 6 5.8 96.3 6 9.4 p 5 0.199
MAP (mm Hg) 80.8 6 4.5 69.3 6 6.3* 82.4 6 9.4 69.5 6 8.4† p 5 0.001
MPAP (mm Hg) 21.8 6 6.7 19.9 6 5.8* 20.8 6 6.1 18.5 6 6.3† p , 0.001
LAP (mm Hg) 8.5 6 2.3 7.6 6 2.7 9.0 6 2.3 7.7 6 2.0† p 5 0.005
CVP (mm Hg) 7.0 6 1.9 6.6 6 2.5 7.1 6 2.2 6.4 6 2.5 p 5 0.153
CO (L z min21) 4.69 6 2.25 4.68 6 2.32 4.80 6 2.27 5.39 6 1.92 p 5 0.003
SV (ml) 51.3 6 20.6 50.2 6 20.4 52.5 6 23.4 55.4 6 18.3 p 5 0.561
SVR (dyne z sec z cm25) 1525 6 683 1273 6 518* 1576 6 906 1043 6 379 p 5 0.012
PVR (dyne z sec z cm25) 290 6 205 265 6 176 249 6 177 185 6 122 p 5 0.227
RVEF (%) 30.1 6 9.8 27.7 6 7.5 29.8 6 7.5 29.7 6 7.7 p 5 0.726
Exact p values are described in the text. ANOVA, Analysis of variance; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; LAP, left atrial
pressure; CVP, central venous pressure; CO, cardiac output; SV, stroke volume; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance; RVEF,
right ventricular ejection fraction.
*p , 0.05 vs baseline.
†p , 0.05 vs repeat baseline.
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sion analysis incorporating all data indicated that
effects of amrinone were significant in altering Ees,
the slope of the ESPAR (p 5 0.007).
Fig. 4 shows the effects of nitroprusside and
amrinone on variables defined by right ventricular
pressure-area loops. A repeated-measures of analy-
sis of variance revealed significant changes in Ao
(p 5 0.029), Ea (p 5 0.002), Ea/Ees (p 5 0.012,) and
EW/PVA (p 5 0.015). As a group, amrinone in-
creased Ees (4.47 6 1.79 mm Hg/cm
2 to 6.56 6 2.22
mm Hg/cm2, p 5 0.007), reduced Ea (8.82 6 3.99
mm Hg/cm2 to 7.05 6 4.01 mm Hg/cm2, p 5 0.004),
and decreased the coupling ratio, Ea/Ees (2.40 6
1.45 to 1.16 6 0.63, p 5 0.009), which resulted in the
increase in EW/PVA (0.44 6 0.15 to 0.54 6 0.15,
p 5 0.013). The increase in this ratio indicates
improvement in the energy transfer from ventricle
to arterial system. With amrinone, A0 significantly
increased (0.26 6 5.09 cm2 to 3.22 6 4.25 cm2, p 5
0.048), but A25 remained unchanged (7.13 6 4.29
cm2 to 7.45 6 4.34 cm2).
The effects of nitroprusside were insignificant.
The slight decrease in EW (66.4 6 26.4 mm
Hg z cm2 to 58.6 6 22.8 mm Hg z cm2) and PVA
(152.5 6 73.5 mm Hg z cm2 to 134.4 6 66.2 mm
Hg z cm2) did not reach statistical significance. Ni-
troprusside decreased mean aortic pressure more
than 10% (from 80.8 6 4.5 mm Hg to 69.3 6 6.3 mm
Hg, p , 0.001), which implied that the dose of
nitroprusside was large enough to influence systemic
circulation.
Hemodynamic variables obtained from the base-
line right ventricular pressure-area loops are shown
in Table II. With nitroprusside, right ventricular
peak-systolic pressure decreased by 8.5% (29.6 6
6.9 mm Hg to 27.1 6 5.1 mm Hg, p 5 0.043), right
ventricular end-systolic pressure decreased by 9.6%
(27.0 6 8.6 mm Hg to 24.4 6 7.4 mm Hg, p 5 0.046)
and maximum right ventricular pressure develop-
ment decreased by 7.8% (232.1 6 83.4 mm Hg/sec
to 213.9 6 72.1 mm Hg/sec, p 5 0.025) with no
change in right ventricular end-diastolic pressure,
Amax, Amin, SA, and FAC.
On the other hand, amrinone decreased right
ventricular peak-systolic pressure in 9 of 11 patients
although there was no significant difference (30.0 6
5.0 mm Hg to 28.4 6 6.3 mm Hg, p 5 0.162). Right
ventricular end-systolic pressure decreased by
Fig. 3. Representative recordings of right ventricular (RV) pressure-area loops before and after nitro-
prusside and amrinone administration obtained by the bolus nitroglycerin intravenously. Lines of the
end-systolic pressure-area relation (Ees; solid lines) and lines of effective arterial elastance (Ea; dotted lines)
are shown. In this case, amrinone increased Ees from 4.3 to 6.3 mm Hg/cm
2, which implied the increase in
right ventricular contractility. On the other hand, amrinone decreased Ea from 10.8 to 7.2 mm Hg/cm
2,
which implied right ventricular afterload reduction.
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16.9% (27.8 6 6.3 mm Hg to 23.1 6 8.2 mm Hg, p 5
0.006), but maximum right ventricular pressure de-
velopment remained unchanged (239.6 6 80.4 mm
Hg/sec to 246.2 6 88.5 mm Hg/sec) with no change
in right ventricular end-diastolic pressure (6.5 6 1.8
mm Hg to 5.7 6 1.9 mm Hg). There was no
significant change in Amax, Amin, and SA. FAC
measured by echocardiography increased in 10 of 11
Fig. 4. Changes in Ees, the intercept of ESPAR (Ao), the area associated with the Pes of 25 mm Hg (A25),
EW, effective Ea, the ratio of Ea to Ees (Ea/Ees), PVA and the efficiency of energy transfer from PVA to
EW (EW/PVA) after administration of nitroprusside and amrinone in the same patients with paired data
sets. Mean 6 SD values are also shown.
Table II. Hemodynamic variables obtained from the baseline RV pressure-area loops
Baseline Nitroprusside Repeat baseline Amrinone
Repeated-measures
of ANOVA
RVPPEAK (mm Hg) 29.6 6 6.9 27.1 6 5.1* 30.0 6 5.0 28.4 6 6.3 p 5 0.005
RVPes (mm Hg) 27.0 6 8.6 24.4 6 7.4* 27.8 6 6.3 23.1 6 82† p , 0.001
RV dp/dtmax (mm Hg/sec) 232.1 6 83.4 213.9 6 72.1* 239.6 6 80.4 246.2 6 88.5 p , 0.001
RVEDP (mm Hg) 5.9 6 1.4 5.6 6 1.8 6.5 6 1.8 5.7 6 1.9† p 5 0.161
Amax (cm
2) 10.0 6 4.8 9.7 6 5.0 10.2 6 4.8 10.0 6 5.3 p 5 0.530
Amin (cm
2) 6.4 6 3.9 6.2 6 4.3 6.7 6 4.2 6.4 6 6.3 p 5 0.414
SA (cm2) 3.7 6 1.2 3.5 6 1.1 3.5 6 1.1 3.7 6 1.2 p 5 0.653
FAC (%) 40.6 6 12.1 42.4 6 17.2 38.5 6 13.4 42.4 6 13.2 p 5 0.314
Exact p values are described in the text. ANOVA, Analysis of variance; RVPPEAK , right ventricular peak-systolic pressure; RVPes , right ventricular end-systolic
pressure; RV dp/dtmax , maximum right ventricular pressure development; RVEDP, right ventricular end-diastolic pressure.
*p , 0.05 vs baseline.
†p , 0.05 vs repeat baseline.
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patients with amrinone, but this difference was not
significant (38.5% 6 13.4% to 42.4% 6 13.2%).
Discussion
We investigated the effects of amrinone on right
ventricular contractility and right ventricular after-
load using the concept of ventricular/arterial cou-
pling. Amrinone reduced afterload (decrease in Ea)
and enhanced contractility (increase in Ees). Ac-
cordingly, there was an improvement in the mechan-
ical efficiency (increased EW/PVA) because of both
afterload reduction and contractility enhancement.
The conventional measures of ventricular func-
tion, such as ejection fraction or cardiac output, are
afterload dependent. Thus it has been difficult to
assess inotropic action of the agents such as amri-
none, which also possesses vasodilatory effect. The
framework of pressure-volume relationship and the
concept of ventricular/arterial coupling made it pos-
sible to separately assess the inotropic and afterload
reducing effects of the agents. This approach has
been applied to study the effects of pharmacologic
agents with inotropic and vasodilatory effects in the
human left ventricle.7-10 Regarding amrinone, Kass
and colleagues11 succeeded in assessing the effects
of amrinone on left ventricular contractility and
afterload using the framework of left ventricular
pressure-volume relationship in the intact canine
left ventricle. In the right ventricle, however, the
number of studies has been limited because of the
difficulty in measuring right ventricular volume.
Using radionuclide ventriculography, Konstam and
colleagues4 studied the effect of amrinone on right
ventricular systolic function. They compared amri-
none and nitroprusside by measuring pulmonary
artery end-systolic pressure and right ventricular
end-systolic volume. They intended to demonstrate
a larger decrease in right ventricular end-systolic
volume with amrinone than with nitroprusside at a
similar systolic pressure. But the difference in right
ventricular end-systolic volume did not reach statis-
tical significance, probably because of the reduced
left ventricular–to–right ventricular interdepen-
dence, which will be discussed later. In addition,
they did not measure right ventricular Ees directly
during amrinone infusion. To the best of our knowl-
edge, our study is the first to demonstrate the inotropic
effect of amrinone on the right ventricle by directly
elucidating the increase in right ventricular Ees.
The assessment of right ventricular Ees was made
possible with the technology of an on-line, real-time
measurement of right ventricular cross-sectional
area as a surrogate for right ventricular volume.12, 13
This technology, ABD, was crucial for investigating
right ventricular pressure-volume relationship, be-
cause instantaneous measurement of right ventricu-
lar pressure and area greatly improved the quality of
study. The standard method of studying the left
ventricular pressure-volume relationship is by use
of a conductance catheter for volume measure-
ment.7-11, 14 In the right ventricle, however, complex
geometry of the right ventricle has hindered the
on-line determination of volume in situ. Accord-
ingly, pressure-volume assessment of the right ven-
tricle has been difficult.15-19 With the ABD technol-
ogy, real-time display of the right ventricular
pressure-area loops became possible at the bedside
of the patient in the intensive care unit.
Feasibility of using the right ventricular cross-
sectional area as a surrogate for right ventricular
volume should be discussed briefly. Morita and
associates20 were the first to use the right ventricular
cross-sectional area to construct human right ven-
tricular pressure-area loops in an intraoperative
cardiac study. They manually traced the endocardial
border of the right ventricle to measure the right
ventricular cross-sectional area. The ABD was first
applied to the human right ventricle by Gorcsan and
his colleagues,12 who demonstrated the inotropic
effect of dobutamine on the right ventricle in pa-
tients with end-stage heart failure. The validation of
this approach was confirmed by Oe and col-
leagues,13 who used isolated canine heart prepara-
tion that contracted isovolumically. They studied the
relation between right ventricular cross-sectional
area obtained by echocardiographic ABD and true
right ventricular volume directly measured by a
balloon placed in the right ventricle with the left
ventricular and right ventricular volumes controlled
independently. They showed a highly linear correla-
tion between the right ventricular area and volume,
demonstrating the validity of the use of area as a
surrogate for volume. We performed a preliminary
intraoperative study that measured volumetric pul-
monary artery flow by an electromagnetic flow
probe and right ventricular cross-sectional area with
ABD. There was a close relationship between the
flow probe–measured stroke volume and SA (the
difference between maximum and minimum cross-
sectional area), which indicated that ABD technol-
ogy may be used to study human right ventricular
function.
In our present study, there was an increase in A0
during amrinone infusion. In our preliminary study
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with dobutamine infusion,21 we observed classic
changes in right ventricular ESPAR, that is, an
increase in Ees with no change in A0. These differ-
ences between dobutamine and amrinone adminis-
tration could be related to the cross-talk from the
left ventricle to the right ventricle. Elzinga and
colleagues22 found that when the left ventricle was
decompressed, right ventricular pump function was
impaired. Yamaguchi and colleagues23 showed, in
an isovolumically contracting isolated canine heart
preparation, that when left ventricular volume was
decreased from 20 ml to 10 ml, Ees decreased by 9%,
and the volume axis intercept of the end-systolic
pressure-volume relation shifted to the right. Morita
and colleagues20 examined the right ventricular ES-
PAR before and after a left ventricular assist device
implantation. After the unloading of the left ventri-
cle by a left ventricular assist device, the right
ventricular ESPAR significantly shifted to the right
(increase in A0). Moon and associates
24 explained
the mechanism of decreased right ventricular pump
performance by the reduced stretch of the ventric-
ular septum, which caused the reduction of the
Frank-Starling mechanism to work in the ventricular
septum. In our preliminary study with dobutamine
infusion,21 there was no change in left atrial pres-
sure, whereas left atrial pressure decreased by 14%
with amrinone in our current study. In addition,
there was no significant decrease in left atrial pres-
sure with nitroprusside. Therefore the shift of the
right ventricular ESPAR to the right with amrinone
could be the result of the reduced left ventricular
volume, provided that there was no alteration in the
left ventricular end-diastolic volume to left atrial
pressure relationship. Further study is warranted to
directly elucidate the mechanism.
The effects of amrinone on right ventricular af-
terload (decrease in Ea) and on contractility (in-
crease in Ees) worked favorably to improve the
mechanical efficiency of the right ventricle (EW/
PVA). The concept of ventricular/arterial coupling
predicts that mechanical efficiency is given by the
formula: EW/PVA 5 1/(1 1 0.5Ea/Ees).
25 In accor-
dance with this prediction, 47% increase in Ees and
20% decrease in Ea resulted in 23% increase in
EW/PVA. The improvement of EW/PVA was
largely due to the increase in EW, whereas nitro-
prusside reduced both EW (12%) and PVA (12%),
which failed to improve EW/PVA. The dosage of
nitroprusside was sufficient to reduce systemic and
pulmonary pressure, which could reflect venodilator
effects that lowered pressures throughout the circu-
lation without any direct reduction in pulmonary
vascular resistance or Ea. Amrinone is thus pre-
ferred to nitroprusside for the purpose of effectively
reducing right ventricular afterload.
The ABD algorithm analyzes backscatter data,
which are affected by ultrasound gain settings.26
Because these gain settings involve manual adjust-
ment based on visual inspection, complete objectiv-
ity of settings cannot be ensured; this is a limitation
of this technique. Moreover, the method of measur-
ing transesophageal echocardiographic area is de-
pendent on the direction and placement of the
echocardiography probe. Large tidal volume venti-
lation may alter the relation of the heart to the
ultrasound sector and thus move the right ventricu-
lar cavity outside of the regionally adjusted gain
settings. We thus selected only end-expiratory beats
for the analyses to minimize the effects of positive-
pressure ventilation. In addition, the operator of the
echocardiographic system was fixed to one person
(Y.O.) throughout this study.
In conclusion, amrinone increased right ventricu-
lar contractility, reduced afterload, and improved
the right ventricular mechanical efficiency. Using
right ventricular pressure-area relations obtained
with transesophageal echocardiography, we could
successfully separate the simultaneous change in
right ventricular systolic mechanics and afterload
caused by amrinone. This methods may be a prom-
ising tool to quantify the relative vasodilating versus
inotropic influences of pharmacologic agents in the
right ventricle and to investigate which drug is most
suitable to treat right ventricular heart failure and
pulmonary hypertension. Amrinone administration
may be beneficial in cardiac surgical patients with
right ventricular dysfunction secondary to postoper-
ative pulmonary hypertension and with primary
right ventricular failure.
This study was prepared in consultation with Yasuhiko
Harasawa, MD, for statistical analyses.
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